Home » 2019

Biotech Stock Spikes On Promising First In-Human CRISPR Gene-Editing Drug

Shares of Crispr Therapeutics (CRSP) jumped Tuesday after the biotech company’s gene-editing approach showed early promise. During the regular session on the stock market today, Crispr stock popped 17%, to 68.46, in above-average volume. At nine months following infusion, the beta thalassemia patient didn’t need a blood transfusion. Four months after...
Read More

Another miracle: CRISPR is gene-editing pain away

Scientists say is a step toward a CRISPR gene therapy that could block severe pain caused by diabetes, cancer, or car accidents without the addictive effects of opioids. The street performer was only 10 years old. He put knives through his arms and walked on...
Read More